An observational study in Hepatocellular Carcinoma, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Shanghai Zhongshan Hospital · Observational
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 240 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Shanghai Zhongshan Hospital is the lead sponsor of 636 studies on the registry; 283 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will enroll male and female subjects with HCC treated with definitive surgery,with or without neoadjuvant therapy.
Exclusion Criteria:
The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.
plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis
Correlation between ctDNA level and recurrence-free survival (RFS)
ctDNA measurements will be made at baseline and 1 months, 3 months, 6 months, 12 months after surgery. RFS will be assessed by standard radiographic imaging.
Time frame: 1 years
Correlation between specific plasma protein expression level and recurrence-free survival (RFS)
plasma proteomic measurements will be made at baseline and 1 months, 3 months, 6 months, 12 months after surgery. RFS will be assessed by standard radiographic imaging.
Time frame: 1 years
Correlation between tumor mutation numbers and recurrence-free survival (RFS)
Patients with available tumor tissues were sequenced to identify their specific tumor variants.The correlation of mutation numbers and RFS will be analysis.
Time frame: 1 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Zhongshan Hospital